Clinical Medicine, Xi'an Medical University, Xi'an, China.
Department of Endocrinology, The Second Affiliated Hospital of Xi'an Medical University, Xi'an, China.
BMC Oral Health. 2023 May 23;23(1):318. doi: 10.1186/s12903-023-02992-2.
Osteoporosis (OP) and periodontal disease (PD) are two common health issues that threaten the older population and potentially connected each other in the context of type 2 diabetes mellitus (T2DM). Dysregulated expression of microRNAs (miRNAs) may contribute to the development and progression of both OP and PD among elderly T2DM patients. The present study aimed to evaluate the accuracy of miR-25-3p expression for the detection of OP and PD when compared to a mixed group of patients with T2DM.
The study recruited 45 T2DM patients with normal bone mineral density (BMD) and healthy periodontium, 40 type 2 diabetic osteoporosis patients coexistent with PD, 50 type 2 diabetic osteoporosis patients with healthy periodontium, and 52 periodontally healthy individuals. miRNA expression measurements in the saliva were determined by real-time PCR.
The salivary expression of miR-25-3p was higher in type 2 diabetic osteoporosis patients than patients with T2DM only and healthy individuals (P < 0.05). Among type 2 diabetic osteoporosis patients, those with PD exhibited a higher salivary expression of miR-25-3p than those with healthy periodontium (P < 0.05). Among type 2 diabetic patients with healthy periodontium, a higher salivary expression of miR-25-3p was noted in those with OP than those without (P < 0.05). We also found a higher salivary expression of miR-25-3p in T2DM patients than healthy individuals (P < 0.05). It was revealed that the salivary expression of miR-25-3p was increased as the T scores of BMD of patients were lowered, the PPD and CAL values of patients were enhanced. The salivary expression of miR-25-3p used as a test to predict a diagnosis of PD among type 2 diabetic osteoporosis patients, a diagnosis of OP among type 2 diabetic patients, and a diagnosis of T2DM among healthy individuals produced AUC of 0.859. 0.824, and 0.886, respectively.
The findings obtained from the study support salivary miR-25-3p confers non-invasive diagnostic potential for PD and OP among a cohort of elderly T2DM patients.
骨质疏松症(OP)和牙周病(PD)是两种常见的健康问题,威胁着老年人群体,并且在 2 型糖尿病(T2DM)的背景下可能相互关联。微小 RNA(miRNA)的失调表达可能导致老年 T2DM 患者的 OP 和 PD 的发生和发展。本研究旨在评估与混合 T2DM 患者组相比,miR-25-3p 表达对 OP 和 PD 检测的准确性。
本研究招募了 45 名 T2DM 患者,其骨密度(BMD)正常且牙周健康,40 名患有 2 型糖尿病骨质疏松症合并 PD 的患者,50 名患有 2 型糖尿病骨质疏松症且牙周健康的患者,以及 52 名牙周健康的个体。通过实时 PCR 测定唾液中的 miRNA 表达。
与仅患有 T2DM 和健康个体相比,2 型糖尿病骨质疏松症患者的唾液中 miR-25-3p 的表达更高(P<0.05)。在 2 型糖尿病骨质疏松症患者中,患有 PD 的患者的唾液 miR-25-3p 表达高于患有牙周健康的患者(P<0.05)。在患有牙周健康的 2 型糖尿病患者中,患有 OP 的患者的唾液 miR-25-3p 表达高于无 OP 的患者(P<0.05)。我们还发现,与健康个体相比,T2DM 患者的唾液 miR-25-3p 表达更高(P<0.05)。结果表明,随着患者的 BMD T 评分降低,PPD 和 CAL 值升高,患者的唾液 miR-25-3p 表达增加。使用 miR-25-3p 作为检测指标来预测 2 型糖尿病骨质疏松症患者的 PD 诊断、2 型糖尿病患者的 OP 诊断和健康个体的 T2DM 诊断,其 AUC 分别为 0.859、0.824 和 0.886。
研究结果支持唾液 miR-25-3p 为老年 T2DM 患者提供了一种非侵入性的 PD 和 OP 诊断潜力。